Previous 10 | Next 10 |
EPALINGES, SWITZERLAND / ACCESSWIRE / August 31, 2022 / Mymetics Corporation (OTCQB:MYMX) a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharma...
Mymetics (MYMX) subsidiary and Insel Gruppe AG have been awarded a grant from the Swiss Innovation Agency, which will allow Mymetics in collaboration with Bern University to start a preclinical study investigating MYMX's virosome-based COVID-19 nasal vaccine candidate to block nasal infection...
Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation ...
Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. Under the TRANSVAC2 program, funded by the European Com...
Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. In May 2020 Mymetics and Baylor College of ...
Mymetics Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine The European vaccine infrastructure, TRANSVAC2, funded by the Eu...
Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics' virosomes were tested by Stallergenes Greer in a therapeutic model of birch pollen allergy. The results showed that a treatment with COP-virosomes was...
Mymetics' ( OTCQB:MYMX ) subsidiary, Mymetics BV, has signed a Research Collaboration Agreement with Baylor College of Medicine and Texas Children's Center for Vaccine Development for evaluating their rationally designed recombinant protein-based SARS-CoV and SARS-CoV-2 antigens ...
Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine Baylor College of Medicine in Texas has deve...
Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...